Monopar Therapeutics Inc (MNPR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $98.31 (-4.27%), Market cap $0.37B, 52-week low–high $30.01 ~ $102.05.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to
Financial statements, price targets, institutional (13F) holdings and related news for Monopar Therapeutics Inc are updated in real time on BlackAll Trade.
Monopar Therapeutics Inc trades at $98.31 (-4.27%). Real-time quotes and charts are available on BlackAll Trade.
Monopar Therapeutics Inc has a market cap of about $0.37B.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage,